Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Float Short %

1.07

Margin Of Safety %

11

Put/Call OI Ratio

0.88

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

0.35

Price

8.87

Target Price

9.85

Analyst Recom

3.33

Performance Q

21.2

Relative Volume

0.56

Beta

0.54

Ticker: GRFS




19 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-06-02GRFS8.310.577.334372
2025-06-03GRFS8.310.581.334396
2025-06-04GRFS8.440.580.694401
2025-06-05GRFS8.710.580.444450
2025-06-06GRFS8.810.595.004479
2025-06-09GRFS8.810.600.024504
2025-06-10GRFS9.010.590.274539
2025-06-11GRFS8.940.590.004585
2025-06-12GRFS8.980.590.004585
2025-06-13GRFS8.850.597.774588
2025-06-16GRFS9.090.650.064815
2025-06-17GRFS8.860.65999.994827
2025-06-18GRFS8.70.650.264842
2025-06-20GRFS8.770.660.004860
2025-06-23GRFS8.360.841.833507
2025-06-24GRFS8.580.861.363566
2025-06-25GRFS8.510.871.253589
2025-06-26GRFS8.770.873.333619
2025-06-27GRFS8.860.880.003632
DateSymbolLastP/C OIP/C VolTotal OI
19 items Current Page1 of 1




19 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-06-02GRFS8.3145.5- 0.85
2025-06-03GRFS8.3445.5- 0.85
2025-06-04GRFS8.4545.5- 0.85
2025-06-05GRFS8.7245.5- 0.85
2025-06-06GRFS8.8245.5- 0.85
2025-06-09GRFS8.8345.5- 0.85
2025-06-10GRFS9.0145.5- 0.85
2025-06-11GRFS8.9345.5- 0.85
2025-06-12GRFS8.9845.5- 0.85
2025-06-13GRFS8.8545.5- 0.85
2025-06-16GRFS9.0945.5- 0.85
2025-06-17GRFS8.8645.5- 0.85
2025-06-18GRFS8.7045.5- 0.85
2025-06-20GRFS8.7745.5- 0.96
2025-06-23GRFS8.3645.5- 0.96
2025-06-24GRFS8.5245.5- 0.95
2025-06-25GRFS8.5045.5- 0.95
2025-06-26GRFS8.7845.5- 0.95
2025-06-27GRFS8.8745.5- 0.95
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
19 items Current Page1 of 1




19 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-06-02GRFS0.00-9.021.47
2025-06-03GRFS0.00-9.021.47
2025-06-04GRFS0.00-9.021.47
2025-06-05GRFS0.00-9.021.47
2025-06-06GRFS0.00-9.021.47
2025-06-09GRFS0.00-8.801.47
2025-06-10GRFS0.00-8.801.47
2025-06-11GRFS0.00-8.801.19
2025-06-12GRFS0.00-8.801.19
2025-06-13GRFS0.00-8.801.19
2025-06-16GRFS0.00-9.181.19
2025-06-17GRFS0.00-9.181.19
2025-06-18GRFS0.00-9.181.19
2025-06-20GRFS0.00-9.181.19
2025-06-23GRFS0.00-9.091.19
2025-06-24GRFS0.00-9.091.19
2025-06-25GRFS0.00-9.091.19
2025-06-26GRFS0.00-9.091.07
2025-06-27GRFS0.00-9.091.07
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
19 items Current Page1 of 1

Last Quarter Act. EPS

Avg. EPS Est. Current Quarter

0.22

Avg. EPS Est. Next Quarter

0.23

Insider Transactions

Institutional Transactions

-9.09

Beta

0.54

Average Sales Estimate Current Quarter

1923

Average Sales Estimate Next Quarter

1906

Fair Value

9.85

Quality Score

56

Growth Score

93

Sentiment Score

79

Actual DrawDown %

56.9

Max Drawdown 5-Year %

-71.8

Target Price

9.85

P/E

28.8

Forward P/E

7.81

PEG

1.18

P/S

0.29

P/B

0.99

P/Free Cash Flow

2.21

EPS

0.31

Average EPS Est. Cur. Y​

0.95

EPS Next Y. (Est.)

1.3

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

2.64

Relative Volume

0.56

Return on Equity vs Sector %

-21.2

Return on Equity vs Industry %

-29.5

EPS 1 7Days Diff

0.1

EPS 1 30Days Diff

0.11

EBIT Estimation

Grifols, S.A.
Sector: Healthcare
Industry: Drug Manufacturers - General
Employees: 23800
Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma, and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factor VIII/von Willebrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease. It also markets diagnostic testing equipment, reagents, and other equipment; offers biological products and manufacturing services; and manufactures and sells plasma to third parties. In addition, the company offers Yimmugo IDP, an immunology drug; Yimmugo PTI, a hematology drug; and Prolastin vials, a pulmonology drug. Further, it develops Xembify Pre-filled syringes, Gamunex Bags, and FlexBag; Xembify Biweekly dosing, Fibrinogen, and VISTASEAL; Prolastin-C AADT and Fostamatinib; Xembify – CLL, Albumina 20% and 5%, and Trimodulin; Alfa-1 AT 15%, GRF6019, GRF6021, Aßvac402, AKST4290, and AKST4290; GIGA 2339 and GIGA564; and recIG, Alfa-1 AT - in non-cystic fibrosis bronchiectasis, and OSIG that are in pre-clinical stage. It has collaboration agreements with Canadian Blood Services to supply grains of Immunoglobulin. The company was founded in 1909 and is headquartered in Barcelona, Spain.
stock quote shares GRFS – Grifols, S.A. Stock Price stock today
news today GRFS – Grifols, S.A. stock forecast ,stock prediction 2023 2024 2025
marketwatch GRFS – Grifols, S.A. yahoo finance google finance
stock history GRFS – Grifols, S.A. invest stock market
stock prices GRFS premarket after hours
ticker GRFS fair value insiders trading